All News
Tofacitinib vs biologics in PsA:
📍MI/stroke ✅ similar
📍Serious infection ✅ similar
📍Malignancy ✅ similar
📍VTE ❌ higher vs TNFi (aHR 0.26)
Large US claims study (n=48k)
Abstract POS0296 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
📊 SIJ findings in PsA (n=581):
🧠 31% = MRI-confirmed axSpA
🦴 Only 29% met r-mNY criteria
MRI-axPsA group: younger, more male, HLA-B27+
Clinical + radiographic definitely underperform vs MRI
#POS0297 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
PsO + recent arthralgia—but no PsA. Treat or wait?
🧠 18% developed PsA in 3 yrs, most in year 1
🔍 Predictors: tender joints, disability, enthesis erosion
Consider early rheum input for these patients
Abstract POS0299 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
Can RZB deliver in real-world early PsA?
💥 9-month results say yes:
✅ Dactylitis gone in 79%
✅ Enthesitis in 90%
✅ 97% MDs & 88% pts satisfied
Early intervention may pay off.
Abstract POS0304 @RheumNow #EULAR2025
Jiha Lee JihaRheum ( View Tweet)
Very pleased to present at #EULAR2025 work @ArthritisAust on consumer involvement into research.
Consumer involvement in research delivers:
- better, more relevant research
- better dissemination of results
- competitiveness in today’s funding landscape
POS1016-PARE @RheumNow https://t.co/0fhpsnGhdT
David Liew drdavidliew ( View Tweet)
High dose NSAIDs and incidence of HTN in axSpA?
In pts with early axSpA(age at baseline 33.2 years) data from DESIR cohort showed that after adjusting for confounders,high dose NSAID use was not associated with incident hypertension (HR 1.01, 95% CI 0.98-1.02).
Interesting to
Adela Castro AdelaCastro222 ( View Tweet)
Rheumatoid nodules are fascinating. If methotrexate nodulosis is a factor, why has their rate gone down when MTX use has gone up?
Environmental factors? Something else? It’s still a bit of a mystery - we still don’t know why
Christopher Edwards #EULAR2025 @RheumNow https://t.co/8LJYNRybve
Links:
David Liew drdavidliew ( View Tweet)
Maybe the pathogenesis gives us a clue on how to target things?
Possibly the treatments which take down synovitis might not always help with nodules
Christopher Edwards #EULAR2025 @RheumNow https://t.co/T6QHCS8709
Links:
David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#POS0320 Data from TULIP+LTE compared to Lupus Toronto Cohort as Control showed Anifrolumab reduced organ damage progression up to 4 years vs real-world SOC in #SLE. Effect continued to 10yrs using novel extrapolate analysis @RheumNow https://t.co/bkjZCZ8xGr
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What is new in SpA?
‼️nomenclature change:
🚫AS≠ Ankylosing spondylitis
✅AS= Axial spondyloarthritis
-Helena Marzo-Ortega at #EULAR2025
@RheumNow
Adela Castro AdelaCastro222 ( View Tweet)
Delay hurts.
Dx delay in axial SpA costs UK £3.1 billion annually.
Avg time to dx = 8.5 yrs
Avg dx cost = £187k/person
Fixing delay could save £167k/person.
Early Dx isn’t just better care—it’s economic policy.
#EULAR2025 @RheumNow
#AxialSpA #RMD https://t.co/eYEQ2rp94m
Jiha Lee JihaRheum ( View Tweet)
@RheumNow So rheumatoid nodule treatment might target some of that pathophysiology. Rituximab, abatacept, or JAKi?
And while surgery often isn’t great (plus they often grow back), definitely an option for some.
Christopher Edwards #EULAR2025 @RheumNow https://t.co/sFWnQN8uC4
Links:
David Liew drdavidliew ( View Tweet)
#Psoriatic_Arthritis
#Preclinical #Early
❓️ Does joint swelling occur in the same anatomical locations affected in the subclinical phase?
🅰️ Yes, in 68%
🅰️ Especially if positive ultrasound
#EULAR2025
@RheumNow
OP0179 by Ivan Giivannini et al. https://t.co/rKfreQyJeG
Nelly ZIADE 🍀 Nellziade ( View Tweet)
#EULAR2025 Abstr#POS0321 In addition to complete renal response attainment as you already know, exploratory analysis from REGENCY showed Obinutuzumab+SOC reduced #lupus nephritis flare and unfavourable kidney outcomes vs PBO+SOC. Longterm kidney survival protection @RheumNow https://t.co/vRFb94TXaQ
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Rheumatoid vasculitis: what to look for and how to find it
#EULAR2025 @AshimaMakol @RheumNow https://t.co/ZCUXgOr1dH
David Liew drdavidliew ( View Tweet)
Acute Dactylitis in #Psoriatic_Arthritis
🔹️1216 patients Canada 🇨🇦
🔹️52% had at least one episode of acute dactylitis in a median 12 years
🔹️Positive association with HLA-B27 and HLA-B27/C02
🔹️No association with HLA-B51
#EULAR2025
@RheumNow
OP0180 by Kharouf et al. https://t.co/oNNMBcvVb4
Nelly ZIADE 🍀 Nellziade ( View Tweet)
How to treat rheumatoid vasculitis
#EULAR2025 @AshimaMakol @RheumNow https://t.co/A8oqPd6bJx
David Liew drdavidliew ( View Tweet)
#EULAR2025 Abstr#OP0324 Cohort study of #lupus nephritis in Greece showed Earlier GC Discontinuation (D/C) & flare protection post-D/C is associated with renal response, low disease activity & HCQ use at GC D/C. Membranous LN & recent diagnosis were assoc w early GC D/C @RheumNow https://t.co/agFgyG5eaS
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Should we still be worried about lymphoma developing in RA patients?
Incidence has plummeted with modern therapy, although still a small risk. TNFi and other bDMARDs don’t seem to confer any real risk.
So what should our approach be?
Karin Hellgren #EULAR2025 @RheumNow https://t.co/9ZodpojSaz
David Liew drdavidliew ( View Tweet)
About #Multidisciplinarity ...
Dr Ihsane Hmamouchi talking about Multidisciplinary Approach to Migrant #Rheumatology Care
#quotes
#EULAR2025
#Invitedspeaker
#outofthebox
@RheumNow
@epirheum https://t.co/RG6xpHejv9
Nelly ZIADE 🍀 Nellziade ( View Tweet)
